LUTERION Co., Ltd. is an IP-holding biotechnology company advancing Lu120819, a mitochondrial-modulating nanoparticle-based investigational therapeutic candidate being developed for diseases involving mitochondrial dysfunction, immune dysregulation, and impaired tissue recovery.
LUTERION Co., Ltd. is the parent company and core intellectual property holder for Lu120819.
LUTERION is building a coordinated development ecosystem around Lu120819 through indication-specific development entities and regional R&D and manufacturing affiliates. This structure enables the group to advance Lu120819 across selected therapeutic areas while maintaining centralized control over core intellectual property, platform strategy, and scientific direction.
Rather than focusing only on downstream disease manifestations, LUTERION's approach is centered on upstream mitochondrial and immune-metabolic biology, where cellular stress, immune dysfunction, and impaired tissue recovery converge.
Lu120819 is Luterion's lead investigational therapeutic platform. The candidate is being developed to modulate mitochondrial and immune-metabolic responses under pathological stress.
LUTERION's scientific strategy is based on the biological connection between mitochondrial dysfunction, maladaptive immune signaling, and impaired recovery after cellular or tissue injury.
Lu120819 is being developed for diseases where mitochondrial dysfunction contributes to pathological stress responses and impaired cellular recovery.
LUTERION's host-directed strategy focuses on immune-metabolic biology rather than direct pathogen- or symptom-only intervention.
The platform is being explored in disease areas involving tissue injury, remodeling, and insufficient recovery from cellular stress.
LUTERION and its affiliated development entities are advancing Lu120819 across selected therapeutic areas where mitochondrial and immune-metabolic dysfunction may play a central role.
Lu120819 is being developed as a host-directed therapeutic approach for viral diseases involving immune-metabolic imbalance and stress-associated host responses.
→ 02Lu120819 is being investigated for cardiovascular disease areas involving tissue injury, pathological remodeling, fibrosis, and mitochondrial dysfunction.
→ 03Lu120819 is being advanced as part of a preparedness-oriented development strategy for high-risk viral threats, including H5N1.
→ 04LUTERION is exploring Lu120819 across diseases in which mitochondrial dysfunction, immune dysregulation, and impaired recovery from cellular stress are biologically connected.
→LUTERION's translational research strategy links mitochondrial function, immune-metabolic signaling, and tissue recovery to development-relevant biomarkers.
Across its research programs, the company evaluates biological readouts related to mitochondrial activity, cellular stress responses, immune function, and tissue remodeling. These translational approaches are designed to support nonclinical development, clinical planning, and indication-specific development decisions while preserving key proprietary data.
Development-relevant readouts related to mitochondrial activity and cellular energy regulation.
Translational assessment of host immune and metabolic responses under pathological stress.
Biological evaluation of tissue injury, fibrosis, remodeling, and recovery-associated pathways.
LUTERION advances Lu120819 through indication-specific development entities and regional R&D and manufacturing affiliates.
The Luterion group has established GMP-grade investigational medicinal product manufacturing capabilities supported by EU QP declaration. Its global development network is designed to support translational research, nonclinical development, clinical coordination, and future manufacturing expansion.
LUTERION also collaborates with academic, clinical, and research institutions across Europe to support animal studies, human ex vivo research, organoid models, and multi-omics investigations.
View Global R&D Network→Parent IP-holding company, BSL-2 mito-immune research infrastructure, company-affiliated research institute, and GMP-grade investigational product manufacturing capabilities through affiliated operations.
EU nonclinical and clinical coordination, joint R&D activities, and future manufacturing and GLP/GMP laboratory expansion.
US-facing development and partnering strategy for selected programs, including H5N1 preparedness.
Academic and clinical collaborations supporting animal studies, human ex vivo research, organoid models, genomics, and proteomics.
Lu120819 is protected by granted patents in the United States, Korea, and other major regions.
LUTERION manages scientific disclosure strategically, sharing selected findings through conference abstracts and scientific presentations while protecting proprietary technology, regulatory development strategy, and long-term platform value.
LUTERION Co., Ltd. owns the core intellectual property related to Lu120819.
Lu120819 is protected by granted patents in the United States, Korea, and other major regions.
LUTERION manages scientific disclosure in alignment with intellectual property protection, regulatory development, and partnering strategy.
LUTERION is open to strategic collaborations, co-development opportunities, and indication-specific partnerships for Lu120819.
Through its affiliated development entities, global R&D network, and GMP-grade investigational product manufacturing capabilities, LUTERION is positioned to support translational research, nonclinical development, clinical coordination, and therapeutic development across multiple disease areas.